Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma
- PMID: 2465644
- DOI: 10.1016/0090-4295(89)90385-3
Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma
Abstract
Orchiectomy is considered a safe and simple procedure, free from serious side effects, in the treatment of prostatic carcinoma. We have found that 76 percent of patients experienced postorchiectomy flushes, and 30 percent believed their symptoms warranted treatment. The flushing started at between one and twelve months (average 2.7 months) postoperatively and lasted an average of thirty months or, in some cases, up to the time of death (average 33 months). No single precipitating factor was found, and no single hormone seemed to be responsible. Special attention was given to the nonflushers to see whether or not it was of prognostic significance, and it appears that the slight elevation in the testosterone level sufficient to prevent flushing may indicate a nontesticular source of androgen. Medroxyprogesterone acetate (Provera), 5 mg twice daily, appeared to be an effective agent for controlling the flushes.
Similar articles
-
The influence of medroxyprogesterone acetate (MPA) on hormone parameters in prostatic carcinoma patients.Int Urol Nephrol. 1988;20(2):131-7. doi: 10.1007/BF02550662. Int Urol Nephrol. 1988. PMID: 2968326
-
[Cyproterone acetate in the treatment of post-orchiectomy flushing].Ugeskr Laeger. 1989 Feb 27;151(9):560-1. Ugeskr Laeger. 1989. PMID: 2522257 Danish.
-
Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone.Urology. 1992 Feb;39(2):108-10. doi: 10.1016/0090-4295(92)90264-w. Urology. 1992. PMID: 1736500 Clinical Trial.
-
Management of hot flushes due to endocrine therapy for prostate carcinoma.Oncology (Williston Park). 1996 Sep;10(9):1319-22; discussion 1324. Oncology (Williston Park). 1996. PMID: 8882924 Review.
-
[Hot flushes in men after surgical or pharmacologic castration].Prog Urol. 1995 Sep;5(4):507-9. Prog Urol. 1995. PMID: 7581499 Review. French.
Cited by
-
Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.CMAJ. 1991 Sep 1;145(5):413-28. CMAJ. 1991. PMID: 1878824 Free PMC article. Review. No abstract available.
-
The Association Between Hot Flashes and Renal Dysfunction After Androgen Deprivation Therapy With Radiotherapy in Japanese Patients With High-risk Prostate Cancer.In Vivo. 2021 Nov-Dec;35(6):3489-3493. doi: 10.21873/invivo.12650. In Vivo. 2021. PMID: 34697186 Free PMC article.
-
The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer.Oncologist. 2012;17 Suppl 1(Suppl 1):23-30. doi: 10.1634/theoncologist.2012-S1-23. Oncologist. 2012. PMID: 23015682 Free PMC article.
-
A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients.Springerplus. 2015 Feb 10;4:65. doi: 10.1186/s40064-015-0808-y. eCollection 2015. Springerplus. 2015. PMID: 25713759 Free PMC article.
-
Acupuncture for hot flashes in patients with prostate cancer.Urology. 2010 Nov;76(5):1182-8. doi: 10.1016/j.urology.2010.03.033. Epub 2010 May 21. Urology. 2010. PMID: 20494414 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical